A recent study conducted by researchers at Washington University School of Medicine in St. Louis has found a link between poor sleep quality and an increased risk of developing Alzheimer’s disease. As Alzheimer’s patients have more orexin-producing neurons in their brains, which disrupts sleep patterns, the FDA-approved insomnia pill known as suvorexant, which blocks orexin, may actually increase the likelihood of developing the disease. The study underscores the importance of good sleep for brain health, particularly for older adults, and urges caution in the use of sleep aids. Additionally, the findings point to potential therapeutic targets for Alzheimer’s treatment that focus on orexin regulation.
Poor Sleep Quality Linked to Alzheimer’s Disease
Researchers at Washington University School of Medicine found a link between poor sleep and Alzheimer's disease, suggesting that the FDA-approved insomnia pill, suvorexant, may increase the risk of developing the disease. Suvorexant works by blocking orexin, a neurotransmitter that regulates wakefulness, and researchers found that Alzheimer's patients have more orexin-producing neurons in their brains, leading to disrupted sleep patterns. The study reinforces the importance of good sleep for brain health and raises concerns about the use of sleep aids in older adults.
Latest from Blog
Manu Chopra, CEO of Karya Inc., emphasized the importance of utilizing artificial intelligence (AI) to reduce
Italy has decided to withdraw from China's Belt and Road Initiative, becoming the only G7 nation
Zerodha's top executives collectively received a remuneration of about ₹200 crore in the financial year 2022-23,
New research suggests that radiotherapy may not be necessary for many patients with ductal carcinoma in
The US Space Force's X-37B space plane is gearing up for its seventh mission, after landing
